Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
نویسندگان
چکیده
References 1. Munzone E, Curigliano G, Rocca A, Bonizzic G, Renne G, Goldhirsch A, Nolè F: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Research 2006, 8:R4 2. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D: Hyperactivation of MAPK induces loss of ERa expression in breast cancer cells. Mol Endocrinol 2001, 15:1344–1359. 3. Holloway JN, Murthy S, El-Ashry D: A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-down-regulation in breast cancer cells: the role of nuclear factor-B. Mol Endocrinol 2004, 18:1396–1410. Correction Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy Elisabetta Munzone1 Giuseppe Curigliano1, Andrea Rocca1, Giuseppina Bonizzi2, Giuseppe Renne3, Aron Goldhirsch1and Franco Nolè1
منابع مشابه
افق‌های پزشکی فردی در درمان سرطان پستان : مقاله مروری
Breast cancer that is caused by the accumulation of genetic and epigenetic alterations, is one of the main causes of death resulted from cancer. Various therapeutic approaches have been introduced for this cancer and the traditional diagnosis and treatment is based on the prognosis estimation using cancer anatomic features (TNM system) and clinical results, but studies show different responses ...
متن کاملTrastuzumab–Docetaxel Combination Chemotherapy Induced Severe Onychopathy
Sir, Taxanes, which are inhibitors of tubulin function in mitosis and used as cancer chemotherapy, are well known to be associated with onychopathy. Trastuzumab, a recombinant DNA‐derived humanized monoclonal antibody against the human epidermal growth factor receptor 2 protein (HER‐2) is used in combination with taxanes in advanced stage HER‐2 positive metastatic breast cancer.[1] We report th...
متن کاملRelation between Estrogen and Progesterone Receptor Status with p53, Ki67 and Her-2 Markers in Patients with Breast Cancer
Background: Breast cancer is the most common cancer in women, containing approximately one third of all illnesses in women. Assessment of molecular markers is valuable in predicting the outcome of disease and decision making for optimal treatment. The purpose of this study was to determine the relationship between estrogen and progesterone receptors with Her-2, Ki67, P53, and clinicopathologica...
متن کاملChange in HER-2/neu Status from Negative to Positive following Treatment in Breast Cancer: A Case Report
INTRODUCTION Approximately 25-30% of breast cancers are assumed to be HER-2/neu positive. It is well known that HER-2/neu-positive cancers after treatment with trastuzumab can become HER-2/neu negative. Change in HER-2/neu status from negative to positive following treatment has not been well studied. We describe a patient with inflammatory breast cancer who was initially HER-2/neu negative but...
متن کاملBone morphogenic protein receptor type 1a (BMPR1A) and Caveolin-1 associated with trastuzumab resistance of breast cancer cells
Trastuzumab is a specific monoclonal antibody used for therapeutic of the human epidermal growth factor receptor 2 (HER-2) -positive metastatic breast cancer. But, resistance to trastuzumab is a major obstacle in clinical efficiency. During the past years, several studies have been done to find the mechanisms contributing to trastuzumab resistance. Previous studies have highlighted that bone m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Breast Cancer Research
دوره 8 شماره
صفحات -
تاریخ انتشار 2006